Page 16 - Biological E News Today

US to provide funds to Biological E for making 1 billion doses by 2022 The United States, through the DFC (Development Finance Corporation), will work with Biological E Ltd, to finance increased capacity to support Biological Es effort to produce at least 1 billion doses of COVID-19 vaccines by the end of 2022 PTI | March 13, 2021 | Updated 08:45 IST The US will provide financial assistance to support Indian drug-maker Biological Es effort to produce at least 1 billion doses of COVID-19 vaccin...

US to provide financial assistance to Indian vaccine maker Biological E The Quad leaders decided to launch a mega vaccine initiative under which coronavirus vaccines will be produced in India for the Indo-Pacific region with financial assistance from the US and Japan, while Australia will contribute in logistical aspects.Premium 2 min read . Updated: 13 Mar 2021, 08:45 AM IST PTI US will work with Biological E Ltd to finance increased capacity to support production of at least 1 billion doses...

March 13, 2021 Biological E Ltds vaccine plant at Shamirpet× Announcement in line with Quad leaders decision to work together on vaccine production, distribution In a major boost to India’s vaccine production drive, the US International Development Finance Corporation (DFC), the country’s development bank, has announced that it will finance Indian manufacturer Biological E Ltd’s effort to produce at least 1 billion doses of Covid-19 vaccines by the end of 2022 which will also include J...

India may have to wait for bridging trialJ&Js deal with Biological E is a global supply agreement and the company will be tapped to meet commitments in Europe and other parts of the world where the company has signed bilateral deals.

3,019,330.0 Three companies — Biological E, Dr Reddy’s Laboratories and Serum Institute of India — are preparing to submit data for approval of their Covid-19 vaccines or to start phase-3 trials, raising hopes of additional supplies for the country’s immunisation programme. Additionally, Bharat Biotech, which received emergency approval for its Covaxin vaccine that’s being used to immunise healthcare workers, will release its phase-3 efficacy data in the next two weeks, chairman Krish...

Indias Biological E looking to make 600 mn J&J vaccine shots a year: CEO Synopsis The countrys inoculation drive is currently using the Oxford University-AstraZeneca vaccine and another developed at home by Bharat Biotech with the state-run Indian Council of Medical Research. Agencies Indian pharmaceutical company Biological E Ltd is looking to contract-manufacture roughly 600 million doses of Johnson and Johnsons COVID-19 vaccine annually, its managing director told Reuters on Wednesday. The c...

Why Johnson & Johnsons Covid-19 vaccine is generating a lot of interest Initial reports indicate the vaccine elicits a very good response. The single-dose vaccine can prove to be a gamechanger, especially in a country with a large population, such as India, where two doses will consume tremendous resources January 18, 2021 / 05:11 PM IST With Johnson & Johnson (J&J)s COVID-19 vaccine Phase-3 clinical trial data expected to be announced before the end of January, followed by an application f...